Silo Pharma announces patent grant for SPC-15, enhancing its development for PTSD treatment in collaboration with Columbia University.
Quiver AI Summary
Silo Pharma, Inc. has announced that IP Australia has granted a patent to Columbia University for a treatment involving serotonin 4 receptor agonists aimed at preventing stress-induced disorders, which is exclusively licensed to Silo. This patent enhances protection for Silo's lead asset, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD) originally developed by Columbia. Silo's CEO Eric Weisblum stated that the patent strengthens their intellectual property portfolio and supports plans for the clinical development of SPC-15 as a new therapeutic for PTSD. The company is also pursuing preclinical studies in partnership with Columbia and has exclusive rights to develop and commercialize SPC-15, which may use the FDA’s expedited 505(b)(2) regulatory pathway. Silo Pharma focuses on treatments for underserved conditions, including psychiatric disorders and chronic pain, collaborating with leading research institutions.
Potential Positives
- IP Australia has granted a patent to Columbia University for Silo Pharma's lead asset, SPC-15, reinforcing the company's intellectual property protection.
- The patent supports the development of SPC-15 as a novel therapeutic for PTSD, which could enhance the company's market position in addressing underserved psychiatric conditions.
- SPC-15's potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway may accelerate its approval process, offering a significant advantage in the competitive biopharmaceutical landscape.
Potential Negatives
- The press release heavily emphasizes forward-looking statements, which may create uncertainty regarding the company's future performance and development timeline for its products.
- There is no mention of any existing clinical trial results for SPC-15, which may raise concerns about the viability and effectiveness of the treatment for PTSD.
- The company is described as "developmental-stage," which implies risks related to funding and the success of unproven products.
FAQ
What is SPC-15 and its intended use?
SPC-15 is an intranasal treatment targeting post-traumatic stress disorder (PTSD) and stress-induced psychiatric disorders.
Who holds the patent for SPC-15?
The patent for SPC-15 is held by Columbia University, which has exclusively licensed it to Silo Pharma.
How does the patent benefit Silo Pharma?
The patent reinforces Silo's global IP portfolio and supports clinical trial development for SPC-15 as a PTSD treatment.
What is the significance of FDA's 505(b)(2) pathway for SPC-15?
The 505(b)(2) pathway may accelerate the regulatory approval process for SPC-15, enhancing its market potential.
What other conditions does Silo Pharma focus on?
Silo Pharma addresses chronic pain, central nervous system diseases, and other underserved conditions alongside stress-related disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (Chief Executive Officer) purchased 10,000 shares for an estimated $4,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 60,000 shares (+48.3%) to their portfolio in Q2 2025, for an estimated $37,800
- TWO SIGMA SECURITIES, LLC added 43,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,227
- RENAISSANCE TECHNOLOGIES LLC removed 37,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,875
- URSA FUND MANAGEMENT, LLC added 37,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,625
- XTX TOPCO LTD added 26,823 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,898
- UBS GROUP AG removed 20,085 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $23,499
- CONNING INC. removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University.
The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University.
“This patent further strengthens our global IP portfolio for SPC-15, protecting its novel approach to preventing stress-induced disorders and enhancing stress resilience,” said Silo CEO Eric Weisblum. “The claims further strengthen and support our plans for clinical trial development of SPC-15 as an innovative therapeutic for PTSD.”
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
